Myasthenia Gravis Market Share, Opportunities and Outlook 2017
Myasthenia gravis is autoimmune neuromuscular disease characterized by weakness and rapid fatigue of any of the muscles under voluntary control. Symptoms include drooping of one or both eyelids, diplopia and difficulty swallowing, chewing and speaking.
Myasthenia gravis is autoimmune neuromuscular disease characterized by weakness and rapid fatigue of any of the muscles under voluntary control. Symptoms include drooping of one or both eyelids, diplopia and difficulty swallowing, chewing and speaking.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Myasthenia</strong> <strong>Gravis</strong> <strong>Market</strong> Pipeline Analysis<br />
<strong>and</strong> Trends Report <strong>2017</strong><br />
“The latest Pharmaceutical <strong>and</strong> Healthcare disease<br />
pipeline guide Gorlin Syndrome (Basal Cell Nevus<br />
Syndrome) - Pipeline Review, H1 <strong>2017</strong>, provides an<br />
overview of the Gorlin Syndrome (Basal Cell Nevus<br />
Syndrome) (Genetic Disorders) pipeline l<strong>and</strong>scape.”<br />
Summary<br />
The latest Pharmaceutical <strong>and</strong> Healthcare disease pipeline guide <strong>Myasthenia</strong> <strong>Gravis</strong> - Pipeline<br />
Review, H1 <strong>2017</strong>, provides an overview of the <strong>Myasthenia</strong> <strong>Gravis</strong> (Immunology) pipeline l<strong>and</strong>scape.<br />
<strong>Myasthenia</strong> gravis is autoimmune neuromuscular disease characterized by weakness <strong>and</strong> rapid<br />
fatigue of any of the muscles under voluntary control. Symptoms include drooping of one or both<br />
eyelids, diplopia <strong>and</strong> difficulty swallowing, chewing <strong>and</strong> speaking. Treatment includes<br />
immunosuppressants, corticosteroids <strong>and</strong> surgery.<br />
Complete Report Available @ http://www.radiantinsights.com/research/myastheniagravis-pipeline-review-h1-<strong>2017</strong><br />
Report Highlights<br />
The Pharmaceutical <strong>and</strong> Healthcare latest pipeline guide <strong>Myasthenia</strong> <strong>Gravis</strong> - Pipeline Review, H1<br />
<strong>2017</strong>, provides comprehensive information on the therapeutics under development for <strong>Myasthenia</strong><br />
<strong>Gravis</strong> (Immunology), complete with analysis by stage of development, drug target, mechanism of<br />
action (MoA), route of administration (RoA) <strong>and</strong> molecule type. The guide covers the descriptive<br />
pharmacological action of the therapeutics, its complete research <strong>and</strong> development history <strong>and</strong><br />
latest news <strong>and</strong> press releases.<br />
Follow Us:
The <strong>Myasthenia</strong> <strong>Gravis</strong> (Immunology) pipeline guide also reviews of key players involved in<br />
therapeutic development for <strong>Myasthenia</strong> <strong>Gravis</strong> <strong>and</strong> features dormant <strong>and</strong> discontinued projects.<br />
The guide covers therapeutics under Development by Companies /Universities /Institutes, the<br />
molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical <strong>and</strong><br />
Discovery stages are 1, 2, 6, 2, 11 <strong>and</strong> 1 respectively. Similarly, the Universities portfolio in Phase<br />
II <strong>and</strong> Preclinical stages comprises 1 <strong>and</strong> 2 molecules, respectively.<br />
<strong>Myasthenia</strong> <strong>Gravis</strong> (Immunology) pipeline guide helps in identifying <strong>and</strong> tracking emerging players<br />
in the market <strong>and</strong> their portfolios, enhances decision making capabilities <strong>and</strong> helps to create<br />
effective counter strategies to gain competitive advantage. The guide is built using data <strong>and</strong><br />
information sourced from the proprietary databases, company/university websites, clinical trial<br />
registries, conferences, SEC filings, investor presentations <strong>and</strong> featured press releases from<br />
company/university sites <strong>and</strong> industry-specific third party sources. Additionally, various dynamic<br />
tracking processes ensure that the most recent developments are captured on a real time basis.<br />
Request a Sample Copy of This Report @<br />
http://www.radiantinsights.com/research/myasthenia-gravis-pipeline-review-h1-<br />
<strong>2017</strong>/request-sample<br />
Scope<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
The pipeline guide provides a snapshot of the global therapeutic l<strong>and</strong>scape of <strong>Myasthenia</strong> <strong>Gravis</strong><br />
(Immunology).<br />
The pipeline guide reviews pipeline therapeutics for <strong>Myasthenia</strong> <strong>Gravis</strong> (Immunology) by<br />
companies <strong>and</strong> universities/research institutes based on information derived from company <strong>and</strong><br />
industry-specific sources.<br />
The pipeline guide covers pipeline products based on several stages of development ranging<br />
from pre-registration till discovery <strong>and</strong> undisclosed stages.<br />
The pipeline guide features descriptive drug profiles for the pipeline products which comprise,<br />
product description, descriptive licensing <strong>and</strong> collaboration details, R&D brief, MoA & other<br />
developmental activities.<br />
The pipeline guide reviews key companies involved in <strong>Myasthenia</strong> <strong>Gravis</strong> (Immunology)<br />
therapeutics <strong>and</strong> enlists all their major <strong>and</strong> minor projects.<br />
The pipeline guide evaluates <strong>Myasthenia</strong> <strong>Gravis</strong> (Immunology) therapeutics based on mechanism<br />
of action (MoA), drug target, route of administration (RoA) <strong>and</strong> molecule type.<br />
The pipeline guide encapsulates all the dormant <strong>and</strong> discontinued pipeline projects.<br />
The pipeline guide reviews latest news related to pipeline therapeutics for <strong>Myasthenia</strong> <strong>Gravis</strong><br />
(Immunology)<br />
Follow Us:
See More Reports of This Category by Radiant Insights @<br />
http://www.radiantinsights.com/catalog/pharmaceuticals-<strong>and</strong>-healthcare<br />
About Radiant Insights, Inc:<br />
Radiant Insights is a platform for companies looking to meet their market<br />
research <strong>and</strong> business intelligence requirements. We assist <strong>and</strong> facilitate<br />
organizations <strong>and</strong> individuals procure market research reports, helping them in<br />
the decision making process. We have a comprehensive collection of reports,<br />
covering over 40 key industries <strong>and</strong> a host of micro markets. In addition to over<br />
extensive database of reports, our experienced research coordinators also offer a<br />
host of ancillary services such as, research partnerships/ tie-ups <strong>and</strong> customized<br />
research solutions.<br />
Contact Details:<br />
Michelle Thoras<br />
Corporate Sales Specialist, USA<br />
Radiant Insights, Inc<br />
28 2nd Street, Suite 3036, San Francisco, CA 94105, United States<br />
Phone: 1-415-349-0054<br />
Toll Free: 1-888-202-9519<br />
Email: sales@radiantinsights.com<br />
Web: http://www.radiantinsights.com/<br />
Visit Our Blog: https://radiantinsightsinc.tumblr.com/<br />
Follow Us:
Change language